Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Global Womens Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Summary

The womens health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The womens health market is relatively small considering the high prevalence of many womens health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within womens health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

Scope

- There are 277 pipeline products in active development for womens health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within womens health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the womens health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the womens health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to womens health products have been completed since 2006. Which types of assets attracted the largest deal values?

Reasons to buy

- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drugs mechanism of action.
- Analyze the womens health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the womens health deals landscape by analyzing trends in licensing and co-development deals.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 11
2.1 Therapy Area Overview 11
2.1.1 Endometriosis 12
2.1.2 Polycystic Ovarin Syndrome 12
2.1.3 Cervical Intraepithelial Neoplasia 12
2.1.4 Menopausal Disorders 12
2.1.5 Infertility 13
2.2 Symptoms 13
2.2.1 Endometriosis 13
2.2.2 Polycystic Ovarian Syndrome 13
2.2.3 Cervical Intraepithelial Neoplasia 14
2.2.4 Menopausal Disorders 14
2.2.5 Infertility 14
2.3 Diagnosis 14
2.3.1 Endometriosis 14
2.3.2 Polycystic Ovarian Syndrome 15
2.3.3 Cervical Intraepithelial Neoplasia 16
2.3.4 Menopausal Disorders 17
2.3.5 Infertility 17
2.4 Etiology and Epidemiology 17
2.4.1 Endometriosis 18
2.4.2 Polycystic Ovarian Syndrome 19
2.4.3 Cervical Intraepithelial Neoplasia 20
2.4.4 Menopause 21
2.4.5 Infertility 21
2.5 Pathophysiology 22
2.5.1 Endometriosis 22
2.5.2 Polycystic Ovarian Syndrome 23
2.5.3 Cervical Intraepithelial Neoplasia 24
2.6 Co-morbidities and Complications 24
2.6.1 Endometriosis 24
2.6.2 Polycystic Ovarian Syndrome 25
2.6.3 Cervical Intraepithelial Neoplasia 26
2.6.4 Menopause and Menopausal Disorders 26
2.6.5 Infertility 27
2.7 Treatment 27
2.7.1 Treatment Options 27
3 Key Marketed Products 33
3.1 Overview 33
3.2 Premarin family (conjugated estrogens) - Pfizer 33
3.3 Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie 35
3.4 Gonal-F (follitropin alfa) - Merck KGaA 36
3.5 Mirena (levonorgestrel) - Bayer 38
3.6 Celebrex (celecoxib) - Pfizer 39
3.7 Implanon/Nexplanon (etonogestrel) - Merck & Co. 40
3.8 Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer 42
3.9 Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co 43
3.10 Gardasil - Merck and Co 44
3.11 Esmya (ulipristal acetate) - Gedoen Richter/Allergan 46
3.12 Orilissa (elagolix sodium) - AbbVie 48
4 Pipeline Landscape Assessment 50
4.1 Overview 50
4.2 Pipeline Development Landscape 51
4.3 Molecular Targets in the Pipeline 54
4.4 Clinical Trials Landscape 56
4.4.1 Clinical Trial Failure Rates 57
4.4.2 Clinical Trial Duration 61
4.4.3 Clinical Trial Size 65
4.4.4 Cumulative Clinical Trial Size 69
4.5 Assessment of Key Pipeline Products 72
4.5.1 Relugolix - Takeda Pharmaceutical Co. Ltd 72
4.5.2 Bremelanotide - AMAG Pharmaceuticals Inc 74
4.5.3 SAGE-217 - Sage Therapeutics Inc. 75
4.5.4 Fezolinetant - Ogeda SA 76
4.5.5 Zulresso - Sage Therapeutics 77
4.5.6 Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid - Inovio Pharmaceuticals Inc 78
4.5.7 Retosiban - GlaxoSmithKline 79
5 Multi-scenario Market Forecast to 2024 81
5.1 Overall Market Size 81
5.2 Generic Penetration 85
5.3 Revenue Forecast by Molecular Target Class 85
5.3.1 G Protein-Coupled Receptor 85
5.3.2 Nuclear Receptor 87
5.3.3 Pathogen 88
5.3.4 Ion Channels/Transporter 89
6 Company Analysis and Positioning 90
6.1 Revenue and Market Share Analysis by Company 92
6.1.1 Bayer AG - Company to Remain a Market Leader within Womens Health 97
6.1.2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Companys Market Share 98
6.1.3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace 99
6.1.4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9 100
6.1.5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth 102
6.1.6 Pfizer - How will patent expiration affect revenues for womens health market? 103
6.1.7 TherapeuticsMD - Womens Health Specialist to Gain Considerable Market Share by 2024 104
6.2 Company Landscape 105
6.3 Marketed and Pipeline Portfolio Analysis 105
7 Strategic Consolidations 108
7.1 Licensing Deals 108
7.1.1 Deals by Region, Value and Year 108
7.1.2 Deals by Key Indication 110
7.1.3 Deals by Stage of Development and Value 111
7.1.4 Deals by Molecule Type, Molecular Target and Value 112
7.1.5 Licensing Deals with Disclosed Values 113
7.2 Co-development Deals 115
7.2.1 Deals by Region, Value and Year 115
7.2.2 Deals by Key Indication 116
7.2.3 Deals by Stage of Development and Value 117
7.2.4 Deals by Molecule Type, Molecular Target and Value 118
7.2.5 Co-development Deals with Disclosed Values 119
8 Appendix 120
8.1 References 120
8.2 Abbreivations 127
8.3 List of All Pipeline Products 128
8.4 Disease List 138
8.5 Methodology 138
8.5.1 Coverage 138
8.5.2 Secondary Research 139
8.5.3 Market Size and Revenue Forecasts 139
8.5.4 Pipeline Analysis 139
8.5.5 Competitive Landscape 140
8.6 Contact Us 140
8.7 Disclaimer 140

List Of Tables

1.1 List of Tables
Table 1: Womens Health Drugs Market, Global, Classification of Cervical Intraepithelial Neoplasia, 2018 12
Table 2: Womens Health Drugs Market, Common Symptoms of the Perimenopause and Menopause, 2018 14
Table 3: Womens Health Drugs Market, Global, Comparison of PCOS Diagnostic Criteria Classification Systems, 2018 16
Table 4: Womens Health Drugs Market, 7MM, Prevalence of Endometriosis, Polycystic Ovarian Syndrome, and Womens Infertility, 2017 18
Table 5: Womens Health Drugs Market, Global, Types of Female Contraceptives, 2018 28
Table 6: Womens Health Drugs Market, Global, Approved Womens Health Indications for Premarin, 2018 34
Table 7: Womens Health Drugs Market, Global, Approved Womens Health Indications for Lupron/Lupron Depot, 2018 35
Table 8: Womens Health Drugs Market, Global, Approved Womens Health Indications for Gonal-F, 2018 37
Table 9: Womens Health Drugs Market, Global, Approved Womens Health Indications for Mirena, 2018 38
Table 10: Womens Health Drugs Market, Global, Approved Womens Health Indications for Celebrex, 2018 39
Table 11: Womens Health Drugs Market, Global, Approved Womens Health Indications for Implanon ,2018 41
Table 12: Womens Health Drugs Market, Global, Approved Womens Health Indications for Yasmin/Yaz, 2018 42
Table 13: Womens Health Drugs Market, Global, Approved Health Indications for Nuvaring, 2018 43
Table 14: Womens Health Drugs Market, Global, Approved Womens Health Indications for Gardasil, 2018 45
Table 15: Womens Health Drugs Market, Global, Approved Womens Health Indications for Esmya, 2018 46
Table 16: Womens Health Drugs Market, Global, Approved Womens Health Indications for Orilissa, 2018 48
Table 17: Womens Health Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 (part 1) 82
Table 18: Womens Health Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 (part 2) 83
Table 19: Womens Health Drugs Market, Global, Forecast Revenue by Company, 2017-2024 92

List Of Figures

1.2 List of Figures
Figure 1: Womens Health Drugs Market, 7MM, Epidemiology Patterns for Endometriosis, 2017-2024 19
Figure 2: Womens Health Drugs Market, 7MM, Epidemiology Patterns for Polycystic Ovarian Syndrome, 2017-2024 20
Figure 3: Womens Health Drugs Market, 7MM, Epidemiology Patterns for Infertility, 2017-2024 22
Figure 4: Womens Health Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 33
Figure 5: Womens Health Drugs Market, Global, Annual Revenue for Premarin ($bn), 2006-2024 35
Figure 6: Womens Health Drugs Market, Global, Annual Revenue for Lupron ($bn), 2006-2024 36
Figure 7: Womens Health Drugs Market, Global, Annual Revenue for Gonal-F ($m), 2017-2024 38
Figure 8: Womens Health Market, Global, Annual Revenue for Mirena ($bn), 2006-2024 39
Figure 9: Womens Health Drugs Market, Global, Annual Revenue for Celebrex ($bn), 2006-2024 40
Figure 10: Womens Health Drugs Market, Global, Annual Revenue for Implanon/Nexplanon ($m), 2007-2024 41
Figure 11: Womens Health Drugs Market, Global, Annual Revenue for Yasmin/Yaz ($bn), 2006-2024 43
Figure 12: Womens Health Drugs Market, Global, Annual Revenue for Nuvaring ($m), 2006-2024 44
Figure 13: Womens Health Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2017-2023 46
Figure 14: Womens Health Drugs Market, Global, Annual Revenue for Esmya ($bn), 2013-2024 47
Figure 15: Womens Health Drugs Market, Global, Annual Revenue for Orilissa ($bn), 2018-2024 49
Figure 16: Womens Health Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 50
Figure 17: Womens Health Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018 51
Figure 18: Womens Health Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 52
Figure 19: Womens Health Market, Global, Pipeline for Key Indications by Molecule Type, 2018 53
Figure 20: Womens Health Drugs Market, Global, Pipeline by Molecular Target, 2018 55
Figure 21: Womens Health Drugs Market, Global, Pipeline for Key Indications by Molecular Target Class, 2018 56
Figure 22: Womens Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006-2018 57
Figure 23: Womens Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2018 58
Figure 24: Womens Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006-2018 59
Figure 25: Womens Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target Class (%), 2006-2018 60
Figure 26: Womens Health Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 61
Figure 27: Womens Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018 62
Figure 28: Womens Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018 63
Figure 29: Womens Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target Class (months), 2006-2018 64
Figure 30: Womens Health Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 65
Figure 31: Womens Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018 66
Figure 32: Womens Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018 67
Figure 33: Womens Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018 68
Figure 34: Womens Health Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 69
Figure 35: Womens Health Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018 70
Figure 36: Womens Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018 71
Figure 37: Womens Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018 72
Figure 38: Womens Health Drugs Market, Global, Revenue Forecast for Relugolix ($m), 2021-2024 73
Figure 39: Womens Health Drugs Market, Global, Annual Revenue Forecast for Bremelanotide ($m), 2019-2024 74
Figure 40: Womens Health Drugs Market, Global, Revenue Forecast for SAGE-217 ($m), 2019-2024 75
Figure 41: Womens Health Drugs Market, Global, Annual Revenue Forecast for Fezolinetant ($m), 2021-2024 76
Figure 42: Womens Health Drugs Market, Global, Revenue Forecast for Zulresso ($m), 2019-2024 77
Figure 43: Womens Health Drugs Market, Global, Revenue Forecast for Bizalimogene Ralaplasmid and Mavilimogene Ralaplasmid ($m), 2021-2024 78
Figure 44: Womens Health Drugs Market, Global, Revenue Forecast for Retosiban ($m), 2019-2024 80
Figure 45: Womens Health Drugs Market, Global, Market Size ($bn), 2017-2024 81
Figure 46: Womens Health Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 85
Figure 47: Womens Health Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Target Class ($bn), 2017-2024 86
Figure 48: Womens Health Drugs Market, Global, Annual Revenue Forecast for Nuclear Receptor Target Class ($bn), 2017-2024 87
Figure 49: Womens Health Drugs Market, Global, Annual Revenue Forecast for Pathogen Target Class ($bn), 2017-2024 88
Figure 50: Womens Health Drugs Market, Global, Annual Revenue Forecast for Ion Channels/Transporters ($bn), 2017-2024 89
Figure 51: Womens Health Drugs Market, Global, Company Analysis Matrix, 2017-2024 90
Figure 52: Womens Health Market, Global, Companies by CAGR and Market Share, 2017-2024 91
Figure 53: Womens Health Drugs Market, Global, Market Share by Company (%), 2017-2024 94
Figure 54: Womens Health Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 95
Figure 55: Womens Health Market, Global, Revenues by Route of Acquisition, 2017-2024 96
Figure 56: Womens Health Drugs Market, Global, Bayer AG Annual Revenue Forecast ($bn), 2017-2024 97
Figure 57: Womens Health Market, Global, AbbVie Inc Annual Revenue Forecast ($bn), 2017-2024 98
Figure 58: Womens Health Market, Global, Allergan Plc Annual Revenue Forecast ($bn), 2017-2024 99
Figure 59: Womens Health Market, Global, Merck& Co. Annual Revenue Forecast ($bn), 2017-2024 101
Figure 60: Womens Health Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2016-2023 102

Global Radioactive Stents Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Radioactive Stents is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

Global Measles, Mumps, and Rubella Virus Vaccine Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Measles, Mumps, and Rubella Virus Vaccine is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX

USD 4000 View Report

Global Women’s Rock Climbing Clothing Market Size study, by Type (Jackets, Pants, Shirts, Others), by Application (Casual, Hiking, Multisport, Snowsports, Running, Others) and Regional Forecasts 2018-2025

Global Womens Rock Climbing Clothing Market valued approximately USD 441.57 million in 2017 is anticipated to grow with a healthy growth rate of more than 16.21% over the forecast period

USD 3950 View Report

Global Women’s Lingerie Market Size study, by Type (Bra, Knickers & Panties, Lounge Wear, Shape Wear, Others), by Application (Online Store, Store Front) and Regional Forecasts 2018-2025

Global Womens Lingerie Market valued approximately USD 35.9 billion in 2017 is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2018-2025. The

USD 3950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available